Vasopressin Effects on Human Social Communication (AVP)

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2013 by Bowdoin College
Sponsor:
Collaborator:
Maine Medical Center
Information provided by (Responsible Party):
Richmond R. Thompson, Bowdoin College
ClinicalTrials.gov Identifier:
NCT01327027
First received: March 30, 2011
Last updated: February 7, 2013
Last verified: February 2013
  Purpose

This research is being done because we wish to understand how a chemical produced in the brain, vasopressin, effects emotional social communication processes. Understanding how this system works in normal individuals may help us understand why some people, particularly those with autism and/or antisocial personality disorder, have dysfunctional social interactions.

This study will test the effects of 3 doses of arginine vasopressin, delivered intranasally, on physiological and behavioral responses to the faces of same- and other-sex individuals in healthy men and women.


Condition Intervention Phase
Healthy
Drug: Vasopressin
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Phase 2 Study of Vasopressin Effects on Human Social Communication

Resource links provided by NLM:


Further study details as provided by Bowdoin College:

Primary Outcome Measures:
  • Emotional Responses [ Time Frame: 60 min ] [ Designated as safety issue: No ]
    Physiological and behavioral measures of emotional responses to faces will be measured 30-60 min after the intranasal delivery of the drug. Specifically, electromyographic responses to same- and other-sex faces of two facial muscles, the corrugator supercilli and the zygomaticus major, will be recorded with surface electrodes, as will electrodermal skin conductance responses and heart rate accelerations. Additionally, subjects will be asked to rate how approachable each face is on a scale where -3 is threatening and not approachable and 3 is friendly and approachable.


Secondary Outcome Measures:
  • Genetic contributions [ Time Frame: 4 years ] [ Designated as safety issue: No ]
    Emotional responses to vasopressin administration will be correlated with polymorphic variation in the gene for the V1a vasopressin receptor. Specifically, the magnitude of the responses discussed above will be correlated with the length of a polymorphic microsatellite region of the V1a promter.


Estimated Enrollment: 300
Study Start Date: September 2011
Estimated Study Completion Date: July 2015
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Vasopressin, Arginine, ADH
We will test how vasopressin affects emotional responses to facial stimuli in healthy men and women.
Drug: Vasopressin
Vasopressin will be dissolved in sterile saline and intranasally delivered in one of 2 doses to each subject (20IU, 40IU)
Placebo Comparator: Sterile Salilne
Sterile saline will be administered intranasally and emotional responses to facial stimuli measured.
Drug: Placebo
Sterile saline will be delivered intranasally on a second test day, in counterbalanced order with vasopressin administration.

Detailed Description:

If you decide to participate you will sign this informed consent and Dr. Price will ask you questions about your medications, medical history, and how you are feeling on that particular day. You will be asked to complete a questionnaire regarding Childhood Trauma and a Brief Psychiatric Rating Scale. You will undergo a brief physical examination which includes an EKG (to look at your heart function), blood pressure and pulse by Dr. Daniel Price at the Maine Medical Center. You will also be asked to provide a urine sample for drug testing and, if you are a female, for pregnancy testing. Individuals with any positive results or results which indicate a need for medical intervention will be confidentially informed by Dr. Price and will not be allowed to participate in this study. Dr. Price will facilitate the transition to medical personnel if needed. Only Dr. Price will be aware of the results from the drug and pregnancy tests, and those results will not be shared with any other members of the research team, Bowdoin administrative officials, law enforcement officers, parents or anybody else.

If you meet the criteria for entry and agree to proceed you will be asked to submit a blood sample so we can analyze the DNA in one of your genes. All results from these tests will be kept strictly confidential and protected with a National Institutes of Mental Health confidentiality certificate. You will be required to report back to Maine Medical Center on three additional days which are one to two days apart. At visit one you will be randomized to receive one of two substances which you will self administer via a spray into your nose. You will self administer the nasal spray at visit one and visit two only. Visit three will not include the administration of the nasal spray. Neither you nor the person administering the testing will be aware if the nasal spray is vasopressin dissolved in sterile saline or sterile saline alone. The nasal spray will be in an applicator which will be provided to you upon your arrival at each study treatment visit. You will be instructed on how to use the nasal sprayer by a member of the study team.

At the start of each of the three study visits, surface skin electrodes will be attached to your palms and forearms to measure skin conductance and heart rate, respectively, and to your face to record muscle activity in your facial muscles. You will then be asked to view a series of facial images while baseline physiological measures are recorded. On the first and second visits 30 minutes following the self administration of the nasal spray, you will view another series of images and answer questions and a 5 ml (approximately one teaspoon) blood sample will be taken from your vein.

On the first and second visit days (when you receive the nasal spray) you will be advised to drink no more than 1 glass of fluid (approx. 8 oz) to prevent excess water retention in response to AVP, and refrain from caffeine consumption two hours before coming to the experiment. On each return visit you will be asked about any medications you may have taken since the last visit. If you have taken any new prescription medication or recreational substances you will not be able to proceed with the study. You will have your blood pressure and temperature measured at baseline, before administration of study drug (pre-dose), again at 5 minutes after study drug administration (post-dose), 20 minutes post dose and 60 minutes post dose. Although it is unlikely, if there are any changes in your blood pressure or body temperature Dr. Price will facilitate the need for any medical attention. If you are feeling well and there are no changes in your blood pressure, pulse or body temperature, you will be able to leave approximately one hour after study drug administration.

Each of the three subsequent visits will last approximately two hours.

  Eligibility

Ages Eligible for Study:   18 Years to 30 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy men and women 21-30 years of age

Exclusion Criteria:

  • individuals with high blood pressure or a history of seizures
  • allergies
  • heart problems
  • psychiatric problems
  • drug abuse
  • pregnant All subjects will be given a preliminary medical and psychiatric exam as well as drug and (for women) pregnancy test
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01327027

Contacts
Contact: Debra D Burris, RN (207) 661-7644 burrid@mmc.org
Contact: Daniel Price, M.D. (207) 662-3510 priced@springharbor.org

Locations
United States, Maine
Maine Medical Center, P6 (Psychiatric Unit) Recruiting
Portland, Maine, United States, 04102
Contact: Debra D Burris, RN, CCRC    207-661-7644    burrid@mmc.org   
Contact: Dan Price, M.D.    (207) 662-3510    priced@springharbor.org   
Principal Investigator: Dan Price, M.D.         
Sponsors and Collaborators
Bowdoin College
Maine Medical Center
Investigators
Principal Investigator: Richmond Thompson, Ph.D. Bowdoin College
  More Information

No publications provided

Responsible Party: Richmond R. Thompson, Ph.D. Associated Professor, Bowdoin College
ClinicalTrials.gov Identifier: NCT01327027     History of Changes
Other Study ID Numbers: 105,108, R01 MH087721-02
Study First Received: March 30, 2011
Last Updated: February 7, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Bowdoin College:
vasopressin
antisocial
affiliation

Additional relevant MeSH terms:
Vasopressins
Arginine Vasopressin
Hemostatics
Coagulants
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Vasoconstrictor Agents
Cardiovascular Agents
Antidiuretic Agents
Natriuretic Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 22, 2014